TaiMed Biologics
TPEX:4147Taipei, Taiwan· Est.
TaiMed Biologics combines CD4‑targeted biologics with CDMO services to address HIV and autoimmune markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
TaiMed Biologics combines CD4‑targeted biologics with CDMO services to address HIV and autoimmune markets.
Infectious DiseasesImmunology
Technology Platform
CD4‑targeted antibody platform enabling both direct antiviral activity (Trogarzo®) and precision delivery of cytotoxic payloads via ADCs for autoimmune indications.
Opportunities
Expansion of long‑acting HIV therapeutics and CD4‑targeted ADCs into high‑growth autoimmune markets, plus scaling CDMO services for global biotech clients.
Risk Factors
Clinical trial outcomes, regulatory approvals, and competition from established HIV and ADC developers could impact commercialization timelines.
Competitive Landscape
TaiMed competes with Gilead/ViiV in HIV and emerging ADC firms in autoimmune space, differentiating through its CD4‑targeted platform and integrated CDMO capabilities.